item management s discussion and analysis of financial condition and results of operations statements of income percent of sales year ended june  revenues operating expenses cost of sales research and development sales and marketing general and administrative income from operations other income expense interest income other  net income before income taxes income tax expense net income year ended june  versus equipment sales and other revenue increased to  in fiscal year  from  in fiscal year sales by product line are summarized as follows revenues by product in thousands fiscal year fiscal year x ray densitometry   ultrasound densitometry   orthopedic imaging   other   the increase in x ray densitometry sales in the current fiscal year is primarily attributable to increased shipments in the united states  which the company believes are related to the introduction of several new drug therapies during the last months 
the increase in orthopedic imaging sales is due to the company s introduction of the orca mini c arm  a portable x ray device used by surgeons to image extremities  and higher artoscan mri sales resulting from increased acceptance of the system  particularly by orthopedic surgeons 
cost of sales as a percentage of equipment sales averaged in the year ended june  and in the year ended june  research and development expenditures remained stable at  in fiscal year compared to  in fiscal year expenditures related to the development of densitometry products increased approximately  over levels offset by the discontinuance of d hormone research 
the company spun off bone care to its shareholders on may  in a transaction intended to qualify as a tax free distribution 
the costs of clinical trials and any other costs related to the research and development of d hormones are not included in the company s consolidated net income after the spin off 
d hormone related expenses were  in fiscal year sales and marketing expenses increased to  of product sales in fiscal year from  of product sales in fiscal year this increase is primarily attributable to increased marketing personnel and sales force placed in position for an expanding market with increased products 
general and administrative expenses increased to  in fiscal year from  in fiscal year legal expenses decreased approximately  lunar had been involved in several patent lawsuits initiated in september with hologic  inc  a massachusetts based competitor  related to x ray and ultrasound densitometers 
these lawsuits were settled in november  offsetting this reduction were increases in labor and other office related costs 
interest income of  in fiscal year approximated interest income of  in fiscal year in december  a court awarded the company and the university of alabama birmingham the co plaintiffs  in a patent infringement case against eg g astrophysics eg g 
the co plaintiffs split the award after deducting legal expenses 
the company s resulting  share of the award is reflected in other income 
the co plaintiffs entered into a settlement and license agreement with eg g providing for future royalty payments based on the volume of eg g equipment sales utilizing the technology subject to the license 
the effective tax rate averaged in fiscal year and in fiscal year the company s effective rate has been below the federal statutory rate as a result of the tax benefit from the company s foreign sales corporation  lunar fsc  inc  and tax exempt interest income offset by the effect of state income taxes 
the effective tax rate was higher in the current fiscal year due to increased profits from sales within the united states  which do not benefit from foreign sales corporation treatment 
year ended june  versus equipment sales and other revenue increased to  in fiscal year  from  in fiscal year sales by product line are summarized as follows revenues by product in thousands fiscal year fiscal year x ray densitometry   ultrasound densitometry   orthopedic imaging   other   the increase in dpx sales in fiscal year is primarily attributable to increased shipments in the united states  which the company believes are related to the introduction of several new drug therapies during the prior months 
the increase in expert shipments is the result of solving several problems related to detector production experienced in prior fiscal years 
achilles sales decreased in fiscal year as compared to fiscal year due to lower sales in japan caused by cutbacks in government sponsored programs to support low cost densitometry 
the increase in artoscan sales is a result of increased acceptance of the system  particularly by orthopedic surgeons 
cost of sales as a percentage of equipment sales increased to in the year ended june  from in the year ended june  this increase is primarily a result of increased sales of the lower margin expert and artoscan extremity mri products  and proportionately less sales of the higher margin achilles 
research and development expenditures increased to  in fiscal year from  in fiscal year this increase is primarily attributable to expenditures related to the development of the dpx iq bone densitometer and the orca mini c arm 
also  bone care increased expenditures for clinical testing of alpha d in the treatment of secondary hyperparathyroidism associated with end stage renal disease 
d hormone related research expenses totaled  in fiscal year compared to approximately  in fiscal year sales and marketing expenses increased to  in fiscal year from  in fiscal year  representing of equipment sales in both years 
during fiscal  lunar expanded the number of direct sales representatives and sales and marketing administration staff in the united states in response to higher customer demand levels 
general and administrative expenses increased to  in fiscal year from  in fiscal year this increase is primarily attributable to higher legal expenses associated with the hologic litigation 
interest income increased to  in fiscal year from  in fiscal year in fiscal year  increased interest income from the company s higher level of financed trade receivables in south america more than offset the decreased interest income from a lower level of marketable securities 
in connection with the bone care spin off the company transferred  to bone care 
the effective tax rate averaged in fiscal year and in fiscal year the company s effective rate is below the federal statutory rate as a result of the tax benefit from the company s foreign sales corporation  lunar fsc  inc  and tax exempt interest income 
the effective tax rate was higher in the current fiscal year due to increased profits from sales within the united states  which do not benefit from foreign sales corporation treatment 
liquidity and capital resources total cash and cash equivalents increased  to  at june  from  at june  marketable securities increased  to  at june  from  at june  marketable securities consist of a laddered portfolio of readily marketable high grade municipal bonds with various maturities not exceeding months 
the company s accounts receivable decreased  to  at june  from  at june  this decrease is attributable to the sale of approximately  of accounts receivable from selected customers in latin america to a leasing company during the year 
the company continues to have recourse of approximately of the sales price in the event non payment of the underlying accounts receivable should occur 
the resulting decrease was partially offset by higher accounts receivable resulting from increases in sales 
inventories increased to  on june  from  on june  this increase is primarily attributable to increased sales 
the company does not have any pending material commitments for capital expenditures 
on april   the company approved a stock repurchase program pursuant to which it may repurchase up to  shares of its common stock from time to time based upon market conditions and other factors 
the company has repurchased  shares under this program as of september  management believes the current level of cash and short term investments is adequate to finance the company s operations for the foreseeable future 
item a 
quantitative and qualitative disclosures about market risk in january  the sec released amended rule of regulations s x general notes to the financial statements  as part of release no 
 requiring additional disclosure with respect to accounting policies followed in connection with the accounting for derivative financial instruments and derivative commodity instruments 
this disclosure is required for all period ending after june   unless a registrant s most recent form k is in compliance 
the release also added item to regulation s k to require quantitative and qualitative disclosures outside the financial statements about market risk inherent in derivative and other financial instruments 
the requirements of item become effective for non bank registrants with market capitalization in excess of billion at january   for filings that include annual financial statements for periods ending after june  for registrants with market capitalization under billion  the requirements of item become effective for filings that include annual financial statements for periods ending after june  the registrant believes it is currently in compliance with amended rule of regulation s x in its most recent form k 
based on the registrant s market capitalization being under billion on january   the requirement of item will commence with its form k for the period ended june   at which time the additional requirements of item will be addressed 

